Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 34, 2017 - Issue 5
Submit an article Journal homepage
578
Views
13
CrossRef citations to date
0
Altmetric
Solid Tumors and Neurooncology

Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma

Frank BertholdDepartment of Pediatric Oncology and Hematology, University of Cologne, GermanyCorrespondence[email protected]
, MD,
Marc HömbergDepartment of Pediatric Oncology and Hematology, University of Cologne, Germany
, MD,
Inna ProleskovskayaDepartment of Pediatric Oncology and Hematology, University of Minsk, Belarus
, MD,
Pavel MazanekDepartment of Pediatric Oncology and Hematology, University of Brno, Czech Republic
, MD,
Margarita BelogurovaDepartment of Pediatric Oncology and Hematology, University of Cologne, St. Petersburg, Russia
, MD,
Angela ErnstInstitute of Medical Statistics, Informatics, and Epidemiology, University of Cologne, Germany
, MSc &
Jaroslav SterbaDepartment of Pediatric Oncology and Hematology, University of Brno, Czech Republic
, MD show all
Pages 308-319 | Received 11 May 2017, Accepted 18 Aug 2017, Published online: 17 Nov 2017

References

  • Annual Report 2013/14 German Childhood Cancer Registry. www.kinderkrebsregister.de p. 39. [Assessed 2016, August 9th]
  • Simon T, Berthold F, Borkhardt A, et al. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: Results of German trials. Pediatr Blood Cancer. 2011;56(4):578–583.
  • Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33:3008–17.
  • Munzone E, Bertonini F. Colleoni M. Metronomic chemotherapy in breast cancer. In: Bocci G, Francia G, eds. Metronomic Chemotherapy. Pharmacology and Clinical Applications. Berlin Heidelberg: Springer-Verlag;2014:93–110.
  • Salvatore L, Zoratto F, Loupakis F, et al. The role of metronomic chemotherapy in the treatment of metastatic colorectal cancer. In: Bocci G, Francia G, eds. Metronomic Chemotherapy. Pharmacology and Clinical Applications. Berlin Heidelberg: Springer-Verlag;2014:135–142.
  • Delos Santos K, Sivanathan L, Lien K, et al. Clinical trials of low-dose metronomic chemotherapy in castration-resistant prostate cancer. In: Bocci G, Francia G, eds. Metronomic Chemotherapy. Pharmacology and Clinical Applications. Berlin Heidelberg: Springer-Verlag;2014:119–134.
  • Meitar D, Crawford SE, Rademaker AW, et al. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol. 1996;14:405–414.
  • Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15–R24.
  • Bruneel A, Labas V, Mailloux A, et al. Proteomics of human umbilical vein endothelial cells applied to etoposide-induced apoptosis. Proteomics. 2005;5:3876–3884.
  • Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003;100:12917–12922.
  • Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;100:39–51.
  • Wang YC, He F, Feng F, et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 2010;70:4840–4849.
  • Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34:336–344.
  • Asgharzadeh S, Salo JA, Ji L, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012;30(28):3525–3532.
  • Nakanishi Y, Nakatsuji M, Seno H, et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis. 2011;32:1333–1339.
  • Kaneko M, Kaneko S, Suzuki K. Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts. Cancer Sci. 2009;100:2193–2201.
  • Tanaka H, Matsushima H, Nishibu A, et al. A Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 2009;69:6987–6994.
  • Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;8:1466–1477.
  • Berthold F, Spix C, Kaatsch P, et al. Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979–2015. Pediatr Drugs 2017. https://doi.org/10.1007/s40272-017-02513
  • Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data, 2nd ed. New York: Springer; 2003.
  • Berthold F, Volland R, Simmon T, et al. Characteristics and risk factors of 517 patients with first recurrence from stage 4 neuroblastoma over 18 months. Advances in Neuroblastoma Research Congress, Cairns, Australia, 19th–23rd. June 2016; Abstract 157:135. www.ANR2016.org→Cairns2016ProgramsandAbstracts(pdf).
  • André N, Carré, Pasquier E. Metronomics: towards personalized chemotherapy? Nature Rev. 2014;11:413–431.
  • Baluch N, Kumar S, Mokhtari R, et al. Metronomic chemotherapy in pediatric malignancies. In: Bocci G, Francia G, eds. Metronomic Chemotherapy. Pharmacology and Clinical Applications. Berlin Heidelberg: Springer-Verlag; 2014:157–172.
  • Pantziarka P, Hutchinson L, André N, et al. Next generation metronomic chemotherapy-report from the fifth biennial international metronomic and anti-angiogenic therapy meeting, 6–8 May 2016, Mumbai. Ecancermedicalscience. 2016;10:689. eCollection2016. PMID 27994645.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.